What Autoimmune Diseases Are Linked to MTHFR?

MTHFR gene variants have been linked, with varying strength of evidence, to a surprisingly wide range of autoimmune conditions, including rheumatoid arthritis, multiple sclerosis, psoriasis, Behçet’s disease, ankylosing spondylitis, and inflammatory bowel disease. The connection is not straightforward: carrying an MTHFR variant does not mean you will develop an autoimmune disease, and many people with autoimmune conditions have perfectly normal MTHFR genes. But a growing body of research, including several large meta-analyses, suggests that these variants modestly raise susceptibility to certain immune-mediated diseases, likely by disrupting the methylation chemistry that helps keep gene expression in check.

What MTHFR Variants Actually Do

The MTHFR gene provides instructions for an enzyme that processes folate (vitamin B9) into its active form, which the body uses to regulate a biochemical process called methylation. Methylation acts like a volume knob for genes: it can turn them up or down without changing the DNA sequence itself. When the MTHFR enzyme works at reduced capacity, less active folate is available, and levels of an amino acid called homocysteine tend to rise.

Two common variants get most of the attention. The C677T variant produces an enzyme with roughly 40 to 45 percent of normal activity in people who carry two copies, and it is the more studied of the two.¹ The A1298C variant reduces enzyme activity to about 68 percent of normal on its own, but when someone carries one copy of each variant together, the combined effect drops activity to around 41 percent.² People who are homozygous for the C677T variant consistently show higher homocysteine levels across different populations, with one large European study finding average levels about 60 percent higher than those with the normal genotype.³

Why does this matter for autoimmunity? Impaired methylation can lead to what researchers call “epigenomic dysfunction,” where genes that should be silenced become active (or vice versa), potentially pushing immune cells toward the kind of overactivity that underlies autoimmune disease.⁴ In rheumatoid arthritis, for instance, T cells and joint tissue show reduced methylation, and MTHFR variants that limit the supply of the body’s main methyl donor compound appear to make this worse. A similar pattern, with immune cells showing aberrant methylation and an inflammatory gene signature, has been documented in lupus and celiac disease.

Rheumatoid Arthritis

Rheumatoid arthritis (RA) has the deepest well of research connecting it to MTHFR. Two independent meta-analyses, each pooling data from more than a dozen studies, found that the C677T variant is associated with a modest but real increase in RA risk. One meta-analysis reported that carrying at least one copy of the T allele raised the odds of RA by about 30 to 38 percent depending on the comparison model used.⁵ The second meta-analysis, based on 16 studies, confirmed a positive link between C677T and RA in several statistical models, and also found that the A1298C variant was associated with RA risk, although only when people carried two copies of the C allele.⁶

There is an additional practical wrinkle. Methotrexate, the most commonly prescribed disease-modifying drug for RA, works by interfering with folate metabolism, the very pathway that MTHFR governs. One study found that the 1298CC genotype was actually associated with fewer methotrexate-related side effects, while patients with the normal 1298AA genotype had more than five times the odds of experiencing adverse reactions.⁷ Other research has looked at whether MTHFR genotype predicts how well methotrexate actually controls RA, with one study finding that certain A1298C genotypes predicted treatment response while C677T did not.⁸ The evidence here is mixed and probably not ready for routine clinical use, but it hints at a future where MTHFR testing could help personalize RA treatment.

Multiple Sclerosis

Multiple sclerosis (MS) stands out as one of the autoimmune conditions with the most consistent MTHFR associations. A broad meta-analysis covering multiple autoimmune diseases found that having two copies of the C677T variant roughly doubled the risk of MS, and the A1298C variant also carried elevated risk.⁹ A study in a southern Iranian population found even stronger associations, with carriers of the 677TT genotype showing about six times the odds of developing MS compared to people with the normal CC genotype. Combined genotype analysis was especially striking: individuals carrying two risk alleles for C677T along with one for A1298C had nearly 14 times the odds.¹⁰

The biological logic is compelling. The MTHFR enzyme is necessary for producing a compound that the central nervous system uses for myelination, the process of building and repairing the protective coating around nerve fibers. MS is fundamentally a disease of myelin destruction, so a genetic variant that impairs the supply chain for myelin repair could plausibly contribute. Research in a German population confirmed that the A1298C variant was associated with the relapsing-remitting form of MS specifically.¹¹ That said, MS is driven by many genetic and environmental factors, and MTHFR is a small piece of a large puzzle.

Behçet’s Disease and Ankylosing Spondylitis

Two less commonly discussed autoimmune conditions showed significant MTHFR associations in the same large meta-analysis that examined MS. Behçet’s disease, an inflammatory condition affecting blood vessels and causing painful ulcers, showed about double the risk in people homozygous for the C677T variant. Ankylosing spondylitis, a chronic inflammatory disease of the spine and joints, showed the strongest association of any condition examined: nearly triple the risk for C677T homozygotes.⁹ These findings are based on fewer individual studies than the RA or MS data, so they deserve further confirmation, but the signal is clear enough to be worth noting.

Psoriasis

Psoriasis, the autoimmune skin condition that causes red, scaly patches, has its own dedicated meta-analysis linking it to MTHFR. Both variants showed positive associations. For C677T, the odds of psoriasis were roughly 70 percent higher in carriers compared to non-carriers, and about twice as high for people who were homozygous. The A1298C variant showed an even more dramatic association, with more than three times the odds in the allele-level comparison.¹² Psoriasis patients often have elevated homocysteine, a known cardiovascular risk factor, which may help explain why people with psoriasis have higher rates of heart disease. The MTHFR connection could be part of this chain, linking the autoimmune skin disease to the metabolic changes that raise cardiovascular risk.

Inflammatory Bowel Disease

The relationship between MTHFR and inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is real but complicated by population differences. An early study found that about 17 percent of both ulcerative colitis and Crohn’s patients were homozygous for C677T, compared to only about 7 percent of healthy controls, roughly a doubling of the variant’s frequency.¹³

But a study in the Israeli Jewish population showed how genetic background matters. Among non-Ashkenazi individuals, carrying the T allele was associated with nearly triple the odds of Crohn’s disease for homozygotes and about double the odds for heterozygotes. Yet the same study found no significant association between MTHFR and ulcerative colitis in the same population, and different ethnic subgroups showed different patterns entirely.¹⁴ This kind of genetic heterogeneity, where the same variant has different effects in different populations, is a recurring theme in MTHFR research and a reason that blanket statements about “MTHFR causes X” are always oversimplified.

Systemic Lupus Erythematosus

Lupus presents a more ambiguous picture. A meta-analysis found that carrying the T allele of C677T was associated with increased lupus risk overall, and the association was especially pronounced in Asian populations, where it reached statistical significance across multiple comparison models.¹⁵ However, another study found no significant difference in MTHFR genotype distribution between lupus patients and controls, even after accounting for race, and found that the variants did not predict higher homocysteine levels in lupus patients.¹⁶

This is the kind of disagreement that is common in genetic association studies. Lupus is notoriously heterogeneous, both genetically and clinically, and it is plausible that MTHFR matters more in certain populations or disease subtypes than in others. The meta-analytic signal pointing toward Asian populations is interesting, but it needs replication before anyone should act on it clinically.

Type 1 Diabetes

The autoimmune form of diabetes has recently drawn attention in MTHFR research. A study combining original data with meta-analysis found that the dominant model of the C677T variant was associated with increased type 1 diabetes risk. Interestingly, the researchers also looked at how MTHFR variants interacted with HLA-DR3 and DR4 alleles, the major genetic risk factors for type 1 diabetes, and found that certain genotype-allele combinations were more common among patients than controls.¹⁷ This is still preliminary, and the authors themselves call for larger studies, but it fits with the broader pattern of MTHFR acting as a background risk modifier that interacts with other genetic factors rather than driving disease on its own.

Autoimmune Thyroid Disease

Not every autoimmune condition shows a clear link to MTHFR, and autoimmune thyroid disease is a useful counterexample. One study that specifically looked at MTHFR C677T and A1298C in relation to autoimmune thyroid disease found no correlation with disease development or prognosis.¹⁸ A study in Jordanian women did find significant differences in A1298C genotype frequency between hypothyroid patients and controls, and between hyperthyroid patients and controls, but the C677T variant showed no association.¹⁹ The pattern here is inconsistent enough that it would be a stretch to list thyroid autoimmunity as clearly MTHFR-linked.

Celiac Disease and Folate Malabsorption

Celiac disease occupies a distinctive niche in the MTHFR conversation. The link is less about MTHFR variants directly causing celiac disease and more about the two conditions compounding each other’s effects. Celiac disease damages the small intestine, which is where folate is absorbed. Since MTHFR enzyme function depends on adequate folate, having both celiac disease and an MTHFR variant creates a double hit: the gene makes the enzyme less efficient, and the gut damage restricts the folate supply the enzyme needs. One study noted that untreated celiac disease can lead to elevated homocysteine through a combination of vitamin deficiencies and MTHFR variants, and that these abnormalities do not always improve with a gluten-free diet alone.²⁰

However, the frequency of the MTHFR T allele does not appear to be significantly different in celiac patients compared to the general population. One study found that about half of celiac patients carried the variant, compared to 48 percent of controls, a statistically meaningless difference.²¹ So MTHFR does not seem to cause celiac disease, but if you have both conditions, the metabolic consequences may be worse than either alone.

When MTHFR Variants Overlap With Clotting Disorders

Some autoimmune conditions, particularly antiphospholipid syndrome (APS), carry a high risk of blood clots. APS is an autoimmune disorder where the immune system attacks proteins involved in blood clotting. When someone has both APS and compound heterozygous MTHFR variants (one copy each of C677T and A1298C), the combined effect on clotting risk can be clinically significant. A reported case of unprovoked thrombosis in a young man highlighted this overlap, where the coexistence of APS and double heterozygous MTHFR mutations with elevated homocysteine created a particularly dangerous thrombotic profile.²² For people with autoimmune conditions that already raise clotting risk, knowing MTHFR status may have practical value, even if the MTHFR variant itself did not cause the autoimmune disease.

Why MTHFR Variants Are So Common

A natural question is: if these variants raise the risk of so many diseases, why are they so widespread? Roughly one in ten North Americans is homozygous for C677T, and the variant is found worldwide. Researchers have proposed that the variant may have provided a survival advantage in certain environments, possibly by redirecting folate toward DNA synthesis during periods of nutritional scarcity. The frequency also varies substantially by region and ethnicity, with some populations showing much higher rates than others, a pattern that could partly reflect genetic drift in historically small populations rather than strong selection pressure.²³ This population variation is one reason that MTHFR associations with autoimmune diseases can look strong in one ethnic group and disappear in another.

Folate, Methylfolate, and What You Can Actually Do

If you carry MTHFR variants and are concerned about autoimmune risk, the single most actionable piece of information is folate status. The enzyme’s reduced efficiency matters most when folate is low; with adequate folate, even people homozygous for C677T often have normal homocysteine levels. This is why the field has largely moved away from MTHFR genotyping as a standalone clinical tool and toward simply checking folate and homocysteine levels directly.

Some clinicians recommend methylfolate (the already-activated form of folate, sometimes labeled L-methylfolate or 5-MTHF) rather than standard folic acid for people with MTHFR variants, since the variants reduce the body’s ability to convert folic acid into its active form. A study in women with MTHFR mutations and recurrent pregnancy loss found that those taking methylfolate had far better outcomes than those on standard folic acid, with only 16 percent experiencing miscarriage in the methylfolate group compared to 54 percent in the standard folate group.²⁴ While that study addressed pregnancy outcomes rather than autoimmune disease directly, the underlying logic extends: if the goal is to support methylation capacity, the form of folate that bypasses the impaired MTHFR enzyme step has a pharmacological rationale.

It is worth noting that most major medical guidelines in the United States and Europe do not currently recommend routine MTHFR testing for autoimmune disease risk assessment. The associations, while statistically significant across meta-analyses, represent modest increases in risk, not the kind of strong predictive value that justifies population-wide screening. MTHFR variants are common, autoimmune diseases involve dozens or hundreds of genes alongside environmental triggers, and the practical intervention (ensuring adequate folate) is something that general nutrition guidelines already recommend for everyone. Where MTHFR testing may genuinely change management is in people who already have an autoimmune diagnosis and are experiencing treatment complications, particularly with methotrexate, or in people with unexplained hyperhomocysteinemia alongside autoimmune symptoms.